STAT+: Pharmalittle: We’re reading about Trump boosting psychedelic treatment, the future for weight-loss drugs, and more
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Eli Lilly CEO David Ricks says GLP‑1 drugs will likely reach at most 50% of eligible patients because of health‑system complexities, comparing to statins where 40‑50% of users are on them.
- Labor Department proposed a rule mandating pharmacy benefit managers to disclose drug pricing data to employers, with a public‑comment deadline last week and over 500 letters submitted.
- Trump order to expand psychedelic treatments has sparked excitement and concern among mental‑health advocates and regulators.
- Mark Cuban and other business leaders support the PBM transparency rule, seeking greater accountability for middlemen.
- PBMs and health insurers are resisting the transparency rule, fearing increased scrutiny.
Why it matters: Eli Lilly and peers can tap a larger slice of the projected $100 billion GLP‑1 market as PBMs lose pricing opacity, while employers gain audit rights, tightening cost control for patients; Trump's psychedelic‑treatment push creates a therapeutic avenue for mental‑health care.
